Mucositis News and Research

RSS

Access selects BioScrip as exclusive distribution and service partner for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip for its lead product, MuGard -- an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

20 Jul 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.

15 Jul 2010

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase(R) to Ohara Pharmaceutical Company Limited. The agreement represents the first product partnership EUSA has established in Japan.

6 Jul 2010

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.

29 Jun 2010

Poster presentation at MASCC Conference summarizes MuGard clinical experience

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy.

28 Jun 2010

Galera Therapeutics completes Series 1 financing

Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc., of Columbia Missouri.

16 Jun 2010

$Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010$

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma, a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European Hematology Association meeting being held June 10-13, 2010 in Barcelona, Spain.

11 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

Periogenix to be introduced at International Symposium for Periodontics & Restorative Dentistry

OroScience plc (Palo Alto, CA), in conjunction with Ace Surgical Supply, Inc. (Brockton, MA), will be exhibiting and introducing Periogenix at the 10th International Symposium for Periodontics & Restorative Dentistry in Boston, Massachusetts from June 10th to 12th, 2010. Sponsored by the International Quintessence Publishing Group, publisher of The International Journal of Periodontics & Restorative Dentistry, and the American Academy of Periodontology, this symposium addresses current trends in periodontal surgery and implant and esthetic dentistry.

10 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

Scientists combine two agents to treat patients with multiple myeloma

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data showing that by combining two treatment agents in the care of multiple myeloma patients, doctors can use higher dosages of chemotherapy before autologous stem cell transplant while alleviating painful and debilitating side effects like severe oral mucositis (mouth ulcers).

8 Jun 2010

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.

8 Jun 2010

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma.

7 Jun 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

New research identifies cellular channel that regulates skin and hair growth

Skin and hair follicles are constantly renewed in the body, maintained by specialized stem cells. New research from Children's Hospital Boston identifies a small cellular channel that regulates skin and hair growth and that could be targeted with small-molecule drugs, potentially treating variety of skin conditions, as well as thinning hair or unwanted hair growth. Findings appear in the April 16, 2010 issue of Cell.

16 Apr 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

JCOM receives approval from KFDA to commercialize MuGard in Korea

ACCESS PHARMACEUTICALS, INC. announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.

26 Mar 2010

Mucositis News and Research

Access selects BioScrip as exclusive distribution and service partner for MuGard

Access announces agreement to develop oral formulation of proprietary injectable drugs

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

Poster presentation at MASCC Conference summarizes MuGard clinical experience

Galera Therapeutics completes Series 1 financing

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Periogenix to be introduced at International Symposium for Periodontics & Restorative Dentistry

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Scientists combine two agents to treat patients with multiple myeloma

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

New research identifies cellular channel that regulates skin and hair growth

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

JCOM receives approval from KFDA to commercialize MuGard in Korea

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News